The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
 
Yazmin Odia
Consulting or Advisory Role - Abbvie; GammaTile
Research Funding - Bristol-Myers Squibb (Inst); Novocure (Inst)
Travel, Accommodations, Expenses - Novocure
 
Ludimila Cavalcante
Employment - Actuate Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics
 
Howard Safran
No Relationships to Disclose
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Vyriad (Inst)
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - CStone Pharmaceuticals; Epigene; Prometheus (I)
Consulting or Advisory Role - Array BioPharma (I); AstraZeneca; Athenex; AtlasMedx; BeiGene; BMSi (I); GenomeSmart; IQvia (I); Jubilant Pharmaceuticals; NeoHealth (I); RasCal; RasCal
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
Wen Wee Ma
Consulting or Advisory Role - Wellstat Therapeutics (Inst)
Research Funding - Actuate Therapeutics (Inst); Athenex (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merrimack (Inst); Sun Pharma (Inst)
 
Benedito A. Carneiro
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Pfizer (Inst)
 
Bruno R. Bastos
Consulting or Advisory Role - AstraZeneca; Bayer; Dendreon; Genzyme; Regeneron
Speakers' Bureau - Sanofi/Regeneron; Seattle Genetics/Astellas
Research Funding - Actuate Therapeutics (Inst); Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Tempest Therapeutics (Inst); Tolero Pharmaceuticals (Inst); US Oncology (Inst)
 
Francis J. Giles
Employment - Actuate Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics
 
Solmaz Sahebjam
Stock and Other Ownership Interests - Abbvie; Allergan
Consulting or Advisory Role - Boehringer Ingelheim; Merck
Research Funding - Bristol-Myers Squibb (Inst); Brooklyn ImmunoTherapeutics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Lilly